利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

59 条记录 (耗时 0.036 秒)

    COMBINATIONS OF MEDICAMENTS FOR THE TREATMENT OF RESPIRATORY DISEASES
    42.
    发明申请
    COMBINATIONS OF MEDICAMENTS FOR THE TREATMENT OF RESPIRATORY DISEASES 审中-公开
    用于治疗呼吸道疾病的药物的组合

    公开(公告)号：US20130189194A1

    公开(公告)日：2013-07-25

    申请号：US13796445

    申请日：2013-03-12

    申请人： Thierry BOUYSSOU ,  Michael P. Pieper ,  Andreas Schnapp

    发明人： Thierry BOUYSSOU ,  Michael P. Pieper ,  Andreas Schnapp

    IPC分类号： A61K31/538 ,  A61K31/439

    CPC分类号： A61K31/538 ,  A61K9/0073 ,  A61K9/0075 ,  A61K9/0078 ,  A61K9/008 ,  A61K9/124 ,  A61K31/40 ,  A61K31/439 ,  A61K31/46 ,  A61K45/06 ,  A61K2300/00

    摘要： A pharmaceutical composition comprising: (a) a compound of formula 1 wherein: n is 1 or 2; R1 is hydrogen, halogen, C1-4-alkyl, or O—C1-4-alkyl; R2 is hydrogen, halogen, C1-4-alkyl, or O—C1-4-alkyl; and R3 is hydrogen, C1-4-alkyl, OH, halogen, O—C1-4-alkyl, O—C1-4-alkylene-COOH, or O—C1-4-alkylene-COO—C1-4-alkyl, or an enantiomer, mixture of enantiomers, or racemate thereof, or an acid addition salt with pharmacologically acceptable acids thereof, or a solvate or hydrate thereof; and (b) another active substance 2, wherein the molar ratio of the compound of formula 1 to the active substance 2 is 1:10 to 12:1.

    摘要翻译： 一种药物组合物，其包含：（a）式1的化合物，其中：n为1或2; R 1是氢，卤素，C 1-4 - 烷基或O-C 1-4 - 烷基; R 2是氢，卤素，C 1-4 - 烷基或O-C 1-4 - 烷基; 和R 3是氢，C 1-4 - 烷基，OH，卤素，O-C 1-4 - 烷基，O-C 1-4 - 亚烷基-COOH或O-C 1-4亚烷基-COO-C 1-4烷基， 或其对映异构体，对映体或其外消旋体的混合物，或其酸加成盐与其可药用酸或其溶剂合物或水合物; 和（b）另一种活性物质2，其中式1化合物与活性物质2的摩尔比为1:10至12:1。

    Substituted naphthyridines and their use as medicaments
    49.
    发明授权
    Substituted naphthyridines and their use as medicaments 有权
    取代的萘啶并用作药物

    公开(公告)号：US08969568B2

    公开(公告)日：2015-03-03

    申请号：US13013973

    申请日：2011-01-26

    申请人： Matthias Hoffmann ,  Georg Dahmann ,  Dennis Fiegen ,  Sandra Handschuh ,  Jasna Klicic ,  Guenter Linz ,  Gerhard Schaenzle ,  Andreas Schnapp ,  Stephen Peter East ,  Michael Philip Mazanetz ,  Robert John Scott ,  Edward Walker

    发明人： Matthias Hoffmann ,  Georg Dahmann ,  Dennis Fiegen ,  Sandra Handschuh ,  Jasna Klicic ,  Guenter Linz ,  Gerhard Schaenzle ,  Andreas Schnapp ,  Stephen Peter East ,  Michael Philip Mazanetz ,  Robert John Scott ,  Edward Walker

    IPC分类号： C07D471/02 ,  C07D471/04 ,  C07D519/00

    CPC分类号： C07D471/04 ,  C07D498/04 ,  C07D519/00

    摘要： The invention relates to new substituted naphthyridines of formula 1, as well as pharmacologically acceptable salts, diastereomers, enantiomers, racemates, hydrates or solvates thereof, wherein R1 is selected from among —O—R3 or —NR3R4, R3 is C1-6-alkyl which is substituted by R5 and R6, R5 is selected from hydrogen, branched or linear C1-6-alkyl, C2-6-alkenyl, —C1-6-alkylen-O—C1-3-alkyl, C1-3-haloalkyl, R6 is ring X wherein n is either 0 or 1, and is a either a single or a double bond and wherein A, B, D and E are each independently from one another selected from CH2, CH, C, N, NH, O or S and wherein ring X is attached to the molecule either via position A, B, D or E, wherein said ring X may optionally be further substituted by one, two or three residues each selected individually from the group consisting of -oxo, hydroxy, —C1-3-alkyl, —C1-3-haloalkyl, —O—C1-3-alkyl, —C1-3-alkanol and halogen, and wherein R4, R2, R7, R8, R9, R10, R11 and Q may have the meanings as given in claim 1, as well as pharmaceutical compositions containing these compounds.

    摘要翻译： 本发明涉及式1的新取代的萘啶，以及其药学上可接受的盐，非对映异构体，对映异构体，外消旋体，水合物或溶剂合物，其中R 1选自-O-R 3或-NR 3 R 4，R 3是C 1-6 - 烷基 其被R5和R6取代，R5选自氢，支链或直链C 1-6 - 烷基，C 2-6 - 烯基，-C 1-6 - 亚烷基-O-C 1-3 - 烷基，C 1-3 - 卤代烷基， R6是环X，其中n是0或1，并且是单键或双键，并且其中A，B，D和E各自独立地选自CH 2，CH，C，N，NH，O 或S，并且其中环X通过位置A，B，D或E连接到分子，其中所述环X可任选地被一个，两个或三个残基进一步取代，每个残基各自独立地选自氧基，羟基 ，-C 1-3 - 烷基，-C 1-3 - 卤代烷基，-O-C 1-3 - 烷基，-C 1-3 - 链烷醇和卤素，其中R4，R2，R7，R8，R9，R10，R11和Q 可能具有的含义 权利要求1中给出，以及含有这些化合物的药物组合物。